The transcription factor p53 is an important regulator of a multitude of cellular processes. In
the presence of genotoxic stress, p53 is activated to facilitate DNA repair, cell cycle arrest …

Since wild-type p53 is central for maintaining genomic stability and preventing oncogenesis,
its coding gene TP53 is highly mutated in~ 50% of human cancers, and its activity is almost …

Objective The aim of this article is to discuss mutant p53 as a possible therapeutic target and
biomarker for breast cancer. Results TP53 (p53) is the most frequently mutated gene in …

Background Cells have evolved balanced mechanisms to protect themselves by initiating a
specific response to a variety of stress. The TP53 gene, encoding P53 protein, is one of the …

Despite huge efforts made in academic and pharmaceutical worldwide research, current
anticancer therapies achieve effective treatment in a limited number of neoplasia cases only …

One of the most notoriously altered genes in human cancer is the tumor-suppressor TP53,
which is mutated with high frequency in more cancers than any other tumor suppressor …

TP53 is a key tumor suppressor gene with protean functions associated with preservation of
genomic balance, including regulation of cellular senescence, apoptotic pathways …

Acute myeloid leukemia (AML) was initially subdivided according to morphology (the French-
American-British system), which proved helpful in pathologic categorization. Subsequently …

p53 missense mutant alleles are present in nearly 40% of all human tumors. Such mutated
alleles generate aberrant proteins that not only lose their tumor-suppressive functions but …

Purpose Triple-negative breast cancer (TNBC) currently lacks an approved targeted therapy.
The tumour suppressor TP53 gene is mutated in approximately 80% of TNBC cases. COTI-2 …